Q3 results were in line – guidance confirmed but marginally negative news.

Weak Q1 results but the speculation remains intact.

2-5% miss across the board in Q1 and guidance cut.

Q1 25 sales and ‘adjusted’ EBITDA were a 3% beat.

Towards a tie up with Abanca or Unicaja?

Beat in Q1 but Wegovy sales are below expectations. FY25 sales guidance downgraded.